141 related articles for article (PubMed ID: 17541036)
1. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
Zundelevich A; Elad-Sfadia G; Haklai R; Kloog Y
Mol Cancer Ther; 2007 Jun; 6(6):1765-73. PubMed ID: 17541036
[TBL] [Abstract][Full Text] [Related]
2. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
[TBL] [Abstract][Full Text] [Related]
3. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
4. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
[TBL] [Abstract][Full Text] [Related]
5. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
6. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
[TBL] [Abstract][Full Text] [Related]
7. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
8. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
9. Novel Ras antagonist blocks human melanoma growth.
Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191
[TBL] [Abstract][Full Text] [Related]
10. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
11. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
12. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
13. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
14. Ras inhibition enhances autophagy, which partially protects cells from death.
Schmukler E; Grinboim E; Schokoroy S; Amir A; Wolfson E; Kloog Y; Pinkas-Kramarski R
Oncotarget; 2013 Jan; 4(1):145-55. PubMed ID: 23370967
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Barkan B; Kloog Y; Ehrlich M
Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
[TBL] [Abstract][Full Text] [Related]
16. Salirasib in the treatment of pancreatic cancer.
Bustinza-Linares E; Kurzrock R; Tsimberidou AM
Future Oncol; 2010 Jun; 6(6):885-91. PubMed ID: 20528225
[TBL] [Abstract][Full Text] [Related]
17. Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
Wolfson E; Schmukler E; Schokoroy ST; Kloog Y; Pinkas-Kramarski R
Biol Cell; 2015 May; 107(5):130-43. PubMed ID: 25735913
[TBL] [Abstract][Full Text] [Related]
18. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
[TBL] [Abstract][Full Text] [Related]
19. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.
Marciano D; Ben-Baruch G; Marom M; Egozi Y; Haklai R; Kloog Y
J Med Chem; 1995 Apr; 38(8):1267-72. PubMed ID: 7731012
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
